Aktuelle Publikationen
Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou JG, Frey B, Donaubauer AJ, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian AO, Fietkau R. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer. 2022 Jan;10(1):e003747. doi: 10.1136/jitc-2021-003747. PMID: 35078923.
Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, Brunner T, Tamaskovics B, Frey B, Zhou JG, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl U, Iro H, Fietkau R, Hecht M. Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers (Basel). 2021 Apr 19;13(8):1959. doi: 10.3390/cancers13081959. PMID: 33921668; PMCID: PMC8073509.
Behrends C, Haussmann J, Kramer PH, Langendijk JA, Gottschlag H, Geismar D, Budach W, Timmermann B. Model-based comparison of organ at risk protection between VMAT and robustly optimised IMPT plans. Z Med Phys. 2021 Feb;31(1):5-15. German. doi: 10.1016/j.zemedi.2020.09.003. Epub 2020 Dec 22. PMID: 33358063.
Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, Brizel D, Budach W, Caudell J, Corry J, Corvo R, Evans M, Garden AS, Giralt J, Gregoire V, Harari PM, Harrington K, Hitchcock YJ, Johansen J, Kaanders J, Koyfman S, Langendijk JA, Le QT, Lee N, Margalit D, Mierzwa M, Porceddu S, Soong YL, Sun Y, Thariat J, Waldron J, Yom SS. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020 Oct;151:314-321. doi: 10.1016/j.radonc.2020.04.019. Epub 2020 Jul 27. PMID: 32730830; PMCID: PMC7384409.
Thomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, Brizel D, Budach W, Caudell J, Corry J, Corvo R, Evans M, Garden AS, Giralt J, Gregoire V, Harari PM, Harrington K, Hitchcock YJ, Johansen J, Kaanders J, Koyfman S, Langendijk JA, Le QT, Lee N, Margalit D, Mierzwa M, Porceddu S, Soong YL, Sun Y, Thariat J, Waldron J, Yom SS. Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618-627. doi: 10.1016/j.ijrobp.2020.04.016. Epub 2020 Apr 14. PMID: 32302681; PMCID: PMC7194855.
Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S, Brunner T, Hinke A, Becker I, Frey B, Semrau S, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Fietkau R. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer. 2020 Oct;8(2):e001378. doi: 10.1136/jitc-2020-001378. PMID: 33023982; PMCID: PMC7539609.
Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rödel C, Hautmann MG, Kölbl O, Salay A, Rübe C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P; PacCis-Study Group. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiother Oncol. 2020 Mar;144:209-217. doi: 10.1016/j.radonc.2020.01.016. Epub 2020 Feb 7. PMID: 32044419.
Haussmann J, Tamaskovics B, Bölke E, Djiepmo-Njanang FJ, Kammers K, Corradini S, Hautmann M, Ghadjar P, Maas K, Schuler PJ, Hoffmann TK, Lammering G, Budach W, Matuschek C. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis. Strahlenther Onkol. 2019 Dec;195(12):1041-1049. English. doi: 10.1007/s00066-019-01511-z. Epub 2019 Oct 4. PMID: 31586229.
Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, Kazmierska J, Langendijk JA, Ozsahin M, O'Sullivan B, Bourhis J, Grégoire V. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiother Oncol. 2019 May;134:1-9. doi: 10.1016/j.radonc.2019.01.018. Epub 2019 Jan 30. PMID: 31005201.
Matuschek C, Haussmann J, Bölke E, Gripp S, Schuler PJ, Tamaskovics B, Gerber PA, Djiepmo-Njanang FJ, Kammers K, Plettenberg C, Anooshahr B, Orth K, Budach W. Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis. Radiat Oncol. 2018 Oct 4;13(1):195. doi: 10.1186/s13014-018-1133-8. PMID: 30286777; PMCID: PMC6172789.
Matuschek C, Bölke E, Geigis C, Kammers K, Ganswindt U, Scheckenbach K, Gripp S, Simiantonakis J, Hoffmann TK, Greve J, Gerber PA, Orth K, Roeder H, Hautmann MG, Budach W. Influence of dosimetric and clinical criteria on the requirement of artificial nutrition during radiotherapy of head and neck cancer patients. Radiother Oncol. 2016 Jul;120(1):28-35. doi: 10.1016/j.radonc.2016.05.017. Epub 2016 Jun 10. PMID: 27296411.
Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers: Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). Strahlenther Onkol. 2016 Aug;192(8):552-60. English. doi: 10.1007/s00066-016-0999-3. Epub 2016 Jun 20. PMID: 27323753.
Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S, Matuschek C. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 2016 Feb;118(2):238-43. doi: 10.1016/j.radonc.2015.10.014. Epub 2015 Nov 14. PMID: 26589131.
Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015 Oct;117(1):83-90. doi: 10.1016/j.radonc.2015.07.041. Epub 2015 Aug 13. PMID: 26277855.
Weber DC, Hurkmans CW, Melidis C, Budach W, Langendijk JH, Peters LJ, Grégoire V, Maingon P, Combescure C. Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer. Radiother Oncol. 2014 Jun;111(3):393-9. doi: 10.1016/j.radonc.2014.04.015. Epub 2014 May 23. PMID: 24861631.
Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24. doi: 10.1016/j.ijrobp.2014.12.034. Epub 2015 Feb 7. PMID: 25670541.
Fairchild A, Langendijk JA, Nuyts S, Scrase C, Tomsej M, Schuring D, Gulyban A, Ghosh S, Weber DC, Budach W. Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis. Radiat Oncol. 2014 Nov 26;9:248. doi: 10.1186/s13014-014-0248-9. PMID: 25424399; PMCID: PMC4311463.
Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Lengele B. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014 Jan;110(1):172-81. doi: 10.1016/j.radonc.2013.10.010. Epub 2013 Oct 31. PMID: 24183870.
Russi EG, Bensadoun RJ, Merlano MC, Bourhis J, Ricardi U, Giralt J, Pinto C, Budach W, Corvò R, Lacouture ME, Bernier J. Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200. Ann Oncol. 2013 Sep;24(9):2463-5. doi: 10.1093/annonc/mdt281. Epub 2013 Jul 29. PMID: 23897703.
Matuschek C, Bölke E, Belka C, Ganswindt U, Henke M, Stegmaier P, Bamberg M, Welz S, Debus J, Gioules A, Voigt A, Volk G, Ohmann C, Wiegel T, Budach V, Stuschke M, Schipper J, Gerber PA, Budach W. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2013 Aug;189(8):625-31. doi: 10.1007/s00066-013-0378-2. Epub 2013 Jul 5. PMID: 23824104.
Gerber PA, Meller S, Eames T, Buhren BA, Schrumpf H, Hetzer S, Ehmann LM, Budach W, Bölke E, Matuschek C, Wollenberg A, Homey B. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res. 2012 Feb 23;17(1):4. doi: 10.1186/2047-783X-17-4. PMID: 22472354; PMCID: PMC3351712.
Niyazi M, Maihoefer C, Krause M, Rödel C, Budach W, Belka C. Radiotherapy and "new" drugs-new side effects? Radiat Oncol. 2011 Dec 21;6:177. doi: 10.1186/1748-717X-6-177. PMID: 22188921; PMCID: PMC3266653.
Budach W, Bölke E, Fietkau R, Buchali A, Wendt TG, Popp W, Matuschek C, Sack H. Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol. 2011 Aug;187(8):449-60. doi: 10.1007/s00066-011-2273-z. Epub 2011 Jul 22. PMID: 21786109.
Bernier J, Russi EG, Homey B, Merlano MC, Mesía R, Peyrade F, Budach W. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol. 2011 Oct;22(10):2191-200. doi: 10.1093/annonc/mdr139. Epub 2011 May 23. PMID: 21606209.
Bölke E, Schieren G, Gripp S, Steinbach G, Peiper M, Orth K, Matuschek C, Pelzer M, Lammering G, Houben R, Antke C, Rump LC, Mota R, Gerber PA, Schuler P, Hoffmann TK, Rusnak E, Hermsen D, Budach W. Cystatin C - a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Strahlenther Onkol. 2011 Mar;187(3):191-201. doi: 10.1007/s00066-010-2203-5. Epub 2011 Feb 24. PMID: 21359659.
Greve J, Bas M, Schuler P, Turowski B, Scheckenbach K, Budach W, Bölke E, Bergmann C, Lang S, Arweiler-Harbeck D, Lehnerdt G, Mattheis S, Bier H, Hoffmann TK. Acute arterial hemorrhage following radiotherapy of oropharyngeal squamous cell carcinoma. Strahlenther Onkol. 2010 May;186(5):269-73. doi: 10.1007/s00066-010-2114-5. Epub 2010 Apr 26. PMID: 20437014.
Berger B, Belka C, Weinmann M, Bamberg M, Budach W, Hehr T. Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol. Strahlenther Onkol. 2010 May;186(5):255-61. doi: 10.1007/s00066-010-2082-9. Epub 2010 Apr 26. PMID: 20437016.
Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009 Feb;90(2):166-71. doi: 10.1016/j.radonc.2008.09.007. Epub 2008 Oct 30. PMID: 18977050.
Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol. 2009 Aug;266(8):1291-300. doi: 10.1007/s00405-008-0846-y. Epub 2008 Oct 30. PMID: 18972123.
Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP; MARCH and MACH-NC Collaborative Groups. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009 Apr;10(4):341-50. doi: 10.1016/S1470-2045(09)70023-3. Epub 2009 Feb 24. PMID: 19246242.
Bölke E, Peiper M, Gripp S. Chemotherapy in unresectable head and neck cancer. N Engl J Med. 2008 Mar 6;358(10):1075; author reply 1075. doi: 10.1056/NEJMc073272. PMID: 18322292.
Bölke E, Gerber PA, Lammering G, Peiper M, Müller-Homey A, Pape H, Giro C, Matuschek C, Bruch-Gerharz D, Hoffmann TK, Gripp S, Homey B, Budach W. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol. 2008 Feb;184(2):105-10. doi: 10.1007/s00066-008-1829-z. PMID: 18259703.
Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007 Aug 2;357(5):514-5. doi: 10.1056/NEJMc071075. PMID: 17671265.
Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006 Jan 31;6:28. doi: 10.1186/1471-2407-6-28. PMID: 16448551; PMCID: PMC1379652.
Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005 Feb 20;23(6):1125-35. doi: 10.1200/JCO.2005.07.010. PMID: 15718308.